Abstract
G. sylvestre (Asclepiadaceae) a vulnerable species is a slow growing, has been shown to display a wide array of pharmacological activities (hypoglycemic and hypolipidemic). The present study was designed to investigate the Antidiabetic effects of Gymnema sylvestre extract in experimental diabetes. Necessary approval from the Institutional Animal Ethics Committee was taken for the study. Experimental diabetes was produced with single dose of Streptozotocin (STZ): 45mg/kg ip. After the confirmation of diabetes on 7th day (>200mg/dl), Gymnema Sylvestre (400mg/kg) was administered orally to experimental rats from day 8th day and continued for 30 days thereafter. Various anti diabetic (Glucose, HbA1C), cardioprotective (CPK-MB), metabolic (Lipid Profile), safety {liver (SGPT, albumin were evaluated in sham (healthy control), STZ- Control and Gymnema treated groups. Administration of STZ resulted in a significant decrease in diabetic changes (increase in blood glucose, HbA1C), cardiac injury (myocardial CPK-MB loss), altered lipid profile, SGPT, Albumin, (p<0.01) in the STZ- control group rats as compared to sham. Gymnema treatment demonstrated significant antidiabetic indicated by restoration of blood glucose, HbA1C and CPK-MB levels (p<0.01) compared to STZ Control group. In addition, Gymnema also favorably modulated the lipid parameters (total cholesterol, triglycerides,). In addition, Gymnema treatment was found to be safe to the liver. The Present study concluded that, the Gymnema Sylvestre extract exhibit the antidiabetic activity.
